Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Alliance Forms With Goal Of Boosting Agency Appropriations

This article was originally published in The Pink Sheet Daily

Executive Summary

Advocacy and education organization has ambitious plan to build membership and present an “alternative budget” by June.

You may also be interested in...



BIO Helps Launch Coalition To Increase FDA Funding, Reduce User Fees Reliance

The Coalition for a Stronger FDA will lobby the administration before shifting its focus to congressional appropriators.

BIO Helps Launch Coalition To Increase FDA Funding, Reduce User Fees Reliance

The Coalition for a Stronger FDA will lobby the administration before shifting its focus to congressional appropriators.

First Generic User Fees Proposed By Deputy Commissioner Gottlieb

GPhA says it would consider user fees for generics if FDA would endorse legislation to speed generics to the market.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS064024

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel